At Least Three Rings In The Polycyclo Ring System Patents (Class 514/250)
-
Patent number: 10138244Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, for use as a human PDE1 inhibitor.Type: GrantFiled: August 18, 2017Date of Patent: November 27, 2018Assignee: Eli Lilly and CompanyInventors: Mark David Rekhter, Qing Shi
-
Patent number: 10081818Abstract: The present invention provides methods for producing cannabinoids and cannabinoid analogs as well as a system for producing these compounds. The inventive method is directed to contacting a compound according to Formula I or Formula II with a cannabinoid synthase. Also described is a system for producing cannabinoids and cannabinoid analogs by contacting a THCA synthase with a cannabinoid precursor and modifying at least one property of the reaction mixture to influence the quantity formed of a first cannabinoid relative to the quantity formed of a second cannabinoid.Type: GrantFiled: February 10, 2017Date of Patent: September 25, 2018Assignee: TEEWINOT TECHNOLOGIES LIMITEDInventors: Richard Peet, Malcolm J. Kavarana, Robert Winnicki, Marc Donsky, Mingyang Sun
-
Patent number: 10072010Abstract: The invention relates to substituted pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]-quinoxaline compounds, represented by Formula 1, defined herein, free base or pharmaceutically acceptable salt forms of the compounds, pharmaceutical compositions thereof, and methods of treating conditions of the central nervous system therewith:Type: GrantFiled: June 21, 2017Date of Patent: September 11, 2018Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Peng Li, Qiang Zhang, Robert Davis, Lawrence P. Wennogle
-
Patent number: 10064860Abstract: Methods for inhibiting the activity of Clostridium difficile in a subject comprises administering to the subject a pharmaceutical composition consisting of clofazimine and at least one pharmaceutically acceptable excipient. Pharmaceutical compositions consisting of clofazimine at least one pharmaceutically acceptable excipient are provided for treating Clostridium difficile infection and diseases or symptoms associated therewith.Type: GrantFiled: December 4, 2017Date of Patent: September 4, 2018Assignee: KamTek, Inc.Inventors: Venkata M. Reddy, Wolf Prensky, Sharanjit VedBrat
-
Patent number: 10035809Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, Z1, and Z4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: GrantFiled: May 18, 2017Date of Patent: July 31, 2018Assignee: GILEAD SCIENCES, INC.Inventors: Elizabeth M. Bacon, Zhenhong R. Cai, Xiaowu Chen, Jeromy J. Cottell, Manoj C. Desai, Mingzhe Ji, Haolun Jin, Scott E. Lazerwith, Michael R. Mish, Philip Anthony Morganelli, Hyung-Jung Pyun, James G. Taylor, Teresa Alejandra Trejo Martin
-
Patent number: 10017517Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.Type: GrantFiled: February 7, 2018Date of Patent: July 10, 2018Assignee: AbbVie Inc.Inventors: Thomas B. Borchardt, Ahmad Y. Sheikh
-
Patent number: 10011604Abstract: Methods for treating a disease or disorder selected from pain, cancer, inflammation, neurodegenerative disease, Typanosoma cruzi infection and osteolytic disease in a mammal, which comprise administering to said mammal a therapeutically effective amount of a compound of Formula I in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification.Type: GrantFiled: December 30, 2015Date of Patent: July 3, 2018Assignee: Array BioPharma, Inc.Inventors: Steven W. Andrews, Julia Haas, Yutong Jiang, Gan Zhang
-
Patent number: 10000482Abstract: The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.Type: GrantFiled: October 18, 2013Date of Patent: June 19, 2018Assignee: ORIGENIS GMBHInventors: Michael Almstetter, Michael Thormann, Andreas Treml, Roland Koestler, Nasser Yehia
-
Patent number: 9963430Abstract: The present invention provides a novel processes for preparation of methyl 3-(benzyloxy)-5-(2,4-difluorobenzylcarbamoyl)-4-oxo-1-(2-oxoethyl)-1,4-dihydropyiridine-2-carboxylate using novel intermediates.Type: GrantFiled: December 14, 2015Date of Patent: May 8, 2018Assignee: Hetero Research FoundationInventors: Bandi Parthasaradhi Reddy, Kura Rathnakar Reddy, Dasari Muralidhara Reddy, Mogili Narsingam, Bandi Vamsi Krishna
-
Patent number: 9962383Abstract: The present invention, among other things, provides compounds, compositions and methods for treatment of cancer. In some embodiments, the present invention provides methods for treating blood cancer using agelastatin alkaloids.Type: GrantFiled: September 2, 2016Date of Patent: May 8, 2018Assignees: Massachusetts Institute of Technology, The Board of Trustees of the University of IllionoisInventors: Mohammad Movassaghi, Paul J. Hergenrother
-
Patent number: 9963459Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.Type: GrantFiled: December 29, 2017Date of Patent: May 8, 2018Assignee: AbbVie Inc.Inventors: Jayanthy Jayanth, Patrick J. Marroum, Peter T. Mayer, Mohamed-Eslam F. Mohamed, Ahmed A. Othman
-
Patent number: 9951080Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.Type: GrantFiled: November 3, 2017Date of Patent: April 24, 2018Assignee: AbbVie Inc.Inventor: Ayman Allian
-
Patent number: 9944635Abstract: This invention in one embodiment is directed to a compound of Formula Ia; where the designation (R) indicates that the designated carbon has the (R) stereochemistry; and wherein Z1 is hydrogen or fluorine; Z2 is hydrogen, deuterium, or fluorine; Z3 is deuterium; Z4 is fluorine; m is an integer from 0 to 10; n is an integer from 0 to 2; provided that: the sum of m+n does not exceed 10; and when both Z1 and Z2 are hydrogen, the sum of m+n is greater than 0, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an antihelminthic agent, such as praziquantel.Type: GrantFiled: December 3, 2015Date of Patent: April 17, 2018Assignee: Concert Pharmaceuticals, Inc.Inventors: Julie F. Liu, Scott L. Harbeson, Roger D. Tung
-
Patent number: 9938244Abstract: The invention relates to a process for manufacturing the compound of formula I wherein R is H, (C1-C6)alkyl or benzyl, or a salt thereof, said process comprising the reaction of the compound of formula I-1 wherein X is Br, Cl or F, or a salt thereof, with the compound of formula I-2 wherein R is H, (C1-C6)alkyl or benzyl, or a salt thereof, in the presence of a base, and, when X is Br or Cl, in the presence of tetra-n-butyl ammonium fluoride hydrate or cesium fluoride. The invention further relates to the compound of formula I-1 and uses thereof.Type: GrantFiled: February 13, 2015Date of Patent: April 10, 2018Assignee: IDORSIA PHARMACEUTICALS LTDInventors: Stefan Abele, Jacques-Alexis Funel, Ivan Schindelholz
-
Patent number: 9926318Abstract: Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.Type: GrantFiled: November 20, 2014Date of Patent: March 27, 2018Assignee: PHARMAKEA, INC.Inventors: John Howard Hutchinson, David Lonergan, Martin Rowbottom, Andiliy Gokching Lai
-
Patent number: 9895328Abstract: Compositions and method for treating a folate-resistant disease in a subject are disclosed. The methods involve administering to the subject an effective amount of a composition containing a formate. For example, the method can be used to reducing the risk of neural tube defects during pregnancy. The method can also be used to treat other conditions normally treatable by folate supplementation.Type: GrantFiled: August 13, 2014Date of Patent: February 20, 2018Assignee: Board of Regents, The University of Texas SystemInventors: Dean R. Appling, Jessica E. Momb
-
Patent number: 9884864Abstract: The present invention is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.Type: GrantFiled: March 9, 2017Date of Patent: February 6, 2018Assignee: Janssen Sciences Ireland UCInventors: Jerôme Emile Georges Guillemont, David Francis Alain Lançois, Magali Madeleine Simone Motte, Anil Koul, Wendy Mia Albert Balemans, Eric Pierre Alexandre Arnoult
-
Patent number: 9879019Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.Type: GrantFiled: August 21, 2017Date of Patent: January 30, 2018Assignee: ABBVIE INC.Inventors: Lars Frederick Nordstroem, Ahmad Y. Sheikh
-
Patent number: 9879018Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.Type: GrantFiled: August 21, 2017Date of Patent: January 30, 2018Assignee: ABBVIE INC.Inventors: Mathew M. Mulhern, Lars Fredrick Nordstroem, Ahmad Y. Sheikh
-
Patent number: 9861576Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.Type: GrantFiled: December 19, 2016Date of Patent: January 9, 2018Assignee: Allergan, Inc.Inventors: Lon T. Spada, Alazar N. Ghebremeskel, Michael R. Robinson
-
Patent number: 9856260Abstract: The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX3CR1 or fractalkine antagonist.Type: GrantFiled: June 6, 2016Date of Patent: January 2, 2018Assignees: Drexel University, Alliance Discovery, Inc.Inventors: Alessandro Fatatis, Joseph M. Salvino, Olimpia Meucci, Whitney L. Gladney
-
Patent number: 9856225Abstract: The present invention provides novel phenazine derivatives, such as compounds of Formula (I) and (II), and pharmaceutically acceptable salts thereof. The compounds of the invention are expected to be antimicrobial agents and may act by a microbial warfare strategy (e.g., a reactive oxygen species (ROS)-based competition strategy). The present invention also provides pharmaceutical compositions, kits, uses, and methods that involve the compounds of the invention and may be useful in preventing or treating a microbial infection (e.g., a bacterial infection) in a subject, inhibiting the growth and/or reproduction of a microorganism (e.g., a bacterium), killing a microorganism (e.g., a bacterium), inhibiting the formation and/or growth of a biofilm, or reducing or clearing a biofilm.Type: GrantFiled: December 23, 2014Date of Patent: January 2, 2018Assignee: University of Florida Research Foundation, IncorporatedInventors: Robert William Huigens, III, Shouguang Jin
-
Patent number: 9855263Abstract: A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.Type: GrantFiled: June 1, 2016Date of Patent: January 2, 2018Assignee: GRÜNENTHAL GMBHInventors: Klaus Wening, Anja Geiβler, Jana Denker, Lutz Barnscheid
-
Patent number: 9849130Abstract: Methods for treating a subject infected with Clostridium difficile comprises administering to the subject a synergistic combination of clofazimine and metronidazole. Pharmaceutical compositions comprising clofazimine and metronidazole are provided for treating Clostridium difficile infection and diseases or symptoms associated therewith.Type: GrantFiled: February 1, 2017Date of Patent: December 26, 2017Assignee: KamTek, Inc.Inventors: Venkata M. Reddy, Wolf Prensky, Sharanjit VedBrat
-
Patent number: 9828344Abstract: The invention relates to dihydropyridine compounds as inhibitors of the notch signalling pathway and/or inhibitors of secretion for the treatment of secretion-dependent disease, such as cancer or senescence-related ageing, in addition to pharmaceutical compositions thereof and methods of treatment.Type: GrantFiled: June 3, 2013Date of Patent: November 28, 2017Assignee: LEIBNIZ-INSTITUT FÜR ALTERSFORSCHUNG FRITZ-LIPMANN-INSTITUT E.V. (FLI)Inventors: Christoph Kaether, Andreas Krämer
-
Patent number: 9820985Abstract: A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.Type: GrantFiled: February 26, 2015Date of Patent: November 21, 2017Assignee: Medivation Technologies LLCInventors: Bing Wang, Daniel Chu
-
Patent number: 9814715Abstract: Provided herein are novel compounds and pharmaceutically acceptable salts thereof that are liver X receptor modulators. Also provided are compositions comprising compounds of the invention and a carrier. Additionally, use of the compounds herein and methods for treating a disease or disorder associated with the liver X receptor are further described.Type: GrantFiled: June 15, 2016Date of Patent: November 14, 2017Assignee: Vitae Pharamceuticals, Inc.Inventors: Chengguo Dong, Yi Fan, Katerina Leftheris, Stephen D. Lotesta, Suresh B. Singh, Colin M. Tice, Wei Zhao, Yajun Zheng, Linghang Zhuang
-
Patent number: 9796723Abstract: Methods for treating a disease or disorder selected from pain, cancer, inflammation, neurodegenerative disease, Typanosoma cruzi infection and osteolytic disease in a mammal, which comprise administering to said mammal a therapeutically effective amount of a compound of Formula I in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification.Type: GrantFiled: January 9, 2017Date of Patent: October 24, 2017Assignee: Array BioPharma, Inc.Inventors: Steven W. Andrews, Julia Haas, Yutong Jiang, Gan Zhang
-
Patent number: 9789107Abstract: A pharmaceutical composition for topical administration including 2,3-dimethyl-6-(N,N-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline(B-220) or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier The composition is useful for the treatment of herpes virus infections of the skin or mucous membranes in a mammal subject.Type: GrantFiled: July 22, 2015Date of Patent: October 17, 2017Assignee: VIRONOVA HERPES ABInventors: Mohammed Homman, Jan Bergman
-
Patent number: 9790236Abstract: An example embodiment relates to an organic semiconductor compound, represented by Chemical Formula 1 herein, which may be polymerized and used in transistors and electronic devices. The organic semiconductor compound includes a base structure of four fused benzene rings with functional groups R1 to R3 connected to a first benzene ring and with functional groups R4 to R6 connected to a second benzene ring. The base structure's third and fourth benzene rings are connected to X1, X2 and X3, X4 respectfully. At least one of X1 and X2 is a sulfur atom. At least one of X3 and X4 is a sulfur atom. The base structure further includes functional groups R7 and R8.Type: GrantFiled: January 12, 2012Date of Patent: October 17, 2017Assignee: Samsung Electronics Co., Ltd.Inventors: Jeong-il Park, Bang Lin Lee, Jong Won Chung
-
Patent number: 9782414Abstract: A novel crystalline form of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection are disclosed. In some embodiments, the novel crystalline form comprises a stable polymorph of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate. The present invention is further directed to a process for the preparation of the novel crystalline form.Type: GrantFiled: January 5, 2017Date of Patent: October 10, 2017Assignee: Array BioPharma, Inc.Inventors: Alisha B. Arrigo, Derrick Juengst, Khalid Shah
-
Patent number: 9771366Abstract: Described herein are carboxamide derivatives of Formula (II) that are useful as inhibitors of p90 ribosomal S6 kinase (RSK), pharmaceutical compositions comprising the derivatives, and methods of using the derivatives in treating diseases or conditions associated with RSK activity: wherein R2, R4a, R4b, R11, R12, and n are defined in the specification.Type: GrantFiled: February 17, 2017Date of Patent: September 26, 2017Assignee: PHOENIX MOLECULAR DESIGNInventors: Sandra E. Dunn, Aarthi Jayanthan, Jaipal Reddy Nagireddy, Subhash Annedi, John H. Van Drie, Timothy S. Daynard, My-my Huynh
-
Patent number: 9757414Abstract: A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.Type: GrantFiled: November 4, 2016Date of Patent: September 12, 2017Assignee: Neurocentria, Inc.Inventors: Guosong Liu, Fei Mao
-
Patent number: 9745273Abstract: Novel phenazine derivatives, methods for their preparation and their medical use, in particular as anti-neoplastic agents and anti-infective agents, are provided. Novel methods for the preparation of iodinin and myxin are also provided.Type: GrantFiled: November 3, 2014Date of Patent: August 29, 2017Assignees: Universitetet I Oslo, Bergen Teknologioverføring AS, Université Claude Bernard Lyon 1Inventors: Stein Ove Døskeland, Pål Rongved, Lars Herfindal, Marc Le Borgne, Elvar Örn Viktorsson, Ove Alexander Høgmoen Åstrand
-
Patent number: 9695191Abstract: Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of type (I) are constituted by three distinct building blocks: an aromatic template a, a conformation modulator b and a spacer moiety c as detailed in the description and the claims. Macrocycles of type (I) are readily manufactured by parallel synthesis or combinatorial chemistry. They are designed to interact with specific biological targets. In particular, they show agonistic or antagonistic activity on the motilin receptor (MR receptor), on the serotonin receptor of subtype 5-HT2B (5-HT2B receptor), and on the prostaglandin F2•receptor (FP receptor). They are thus potentially useful for the treatment of hypomotility disorders of the gastrointestinal tract such as diabetic gastroparesis and constipation type irritable bowl syndrome; of CNS related diseases like migraine, schizophrenia, psychosis or depression; of ocular hypertension such as associated with glaucoma and preterm labour.Type: GrantFiled: August 5, 2009Date of Patent: July 4, 2017Assignee: POLYPHOR AGInventors: Daniel Obrecht, Philipp Ermert, Said Oumouch, Franck Lach, Anatol Luther, Karsten Marx, Kerstin Möhle
-
Patent number: 9663528Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, Z1, and Z4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: GrantFiled: July 31, 2015Date of Patent: May 30, 2017Assignee: Gilead Sciences, Inc.Inventors: Manoj C. Desai, Haolun Jin, Scott E. Lazerwith, Hyung-Jung Pyun, James G. Taylor
-
Patent number: 9657017Abstract: The present invention relates to a crystal form of (R)-praziquantel and a preparation method and uses thereof. The X-ray diffraction pattern (CuK? radiation) of the crystal form of (R)-praziquantel at 25° C. shows the following diffraction peaks: 2-Theta =6.9±0.2°, 8.3±0.2°, 15.1±0.2°, 17.4±0.2°, 19.8±0.2°, 21.9±0.2°, 24.3 ±0.2° or d=12.74±0.20 ?, 10.61±0.20 ?, 5.87±0.20 ?, 5.09±0.20 ?, 4.48±0.20 ?, 4.06±0.20 ?, 3.66±0.20 ?. Compared to the existing crystal form of praziquantel, the crystal form of the present invention has better solubility, better drug efficacy and better pharmacokinetic characteristics. The preparation method of the present invention has the following advantages: good reproducibility, environmentally friendly, low cost, and able to operate at a normal pressure and temperature, and suitable for large-scale production.Type: GrantFiled: October 16, 2014Date of Patent: May 23, 2017Assignee: Tongli Biomedical Co., Ltd.Inventors: Mingxin Qian, Rodney JY Ho, Chunsheng Qiao, Junwei Shi
-
Patent number: 9630978Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (Ia): including stereoisomers and pharmaceutically acceptable salts thereof, wherein A, A?, R1 and R2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: GrantFiled: April 1, 2016Date of Patent: April 25, 2017Assignee: GILEAD SCIENCES, INC.Inventors: Zhenhong R. Cai, Haolun Jin, Scott E. Lazerwith, Hyung-Jung Pyun
-
Patent number: 9617262Abstract: The present invention is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.Type: GrantFiled: March 16, 2016Date of Patent: April 11, 2017Assignee: Janssen Sciences Ireland UCInventors: Jerome Emile Georges Guillemont, David Francis Alain Lancois, Magali Madeleine Simone Motte, Anil Koul, Wendy Mia Albert Balemans, Eric Pierre Alexandre Arnoult
-
Patent number: 9617310Abstract: Compounds of formula I: or pharmaceutically acceptable salts thereof, wherein the various substituents are defined herein, methods of using said compounds, and pharmaceutical compositions containing said compounds.Type: GrantFiled: March 14, 2014Date of Patent: April 11, 2017Assignee: Gilead Sciences, Inc.Inventors: Kyla L. Bjornson, Kapil K. Karki, John O. Link, Hyung-jung Pyun, Adam J. Schrier, Kirk L. Stevens, James G. Taylor, Randall W. Vivian, Jeff Zablocki, Sheila Zipfel
-
Patent number: 9586960Abstract: The present invention relates to toluenesulfonic acid addition salt crystals of 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3?,4?: 4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone, and methods of using such crystals as 5-hydroxytryptamine 2 receptor agonists and antagonists in treating disorders of the central nervous system.Type: GrantFiled: November 30, 2015Date of Patent: March 7, 2017Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: John Tomesch, Lawrence P. Wennogle
-
Patent number: 9540336Abstract: The present invention includes a method of treating or preventing a disease or disorder such as a mycobacterial infection, a Gram-positive bacterium infection, a yeast infection, an inflammatory condition, an auto-immune disorder and/or a proliferative disorder in a subject in need thereof. The method comprises administering to the subject a therapeutically effective amount of at least one compound of the invention, which includes clofazimine derivatives.Type: GrantFiled: December 21, 2012Date of Patent: January 10, 2017Assignee: The Trustees of the University of PennsylvaniaInventors: Harvey Rubin, Takahiro Yano, Sacha Kassovska-Bratinova, Norman Schechter, Jiah Shin Teh, Jeffrey Winkler
-
Patent number: 9540387Abstract: The present invention relates to compounds of formula (I) its salts, isomers or prodrugs thereof useful in the treatment of viral infections, in particular respiratory syncytial virus (RSV) infections. The present invention also relates to processes for preparing the compounds and intermediates used in their preparation.Type: GrantFiled: October 20, 2015Date of Patent: January 10, 2017Assignee: BIOTA SCIENTIFIC MANAGEMENT PTY LTD.Inventors: Jeffrey Peter Mitchell, Gary Pitt, Alistair George Draffan, Penelope Anne Mayes, Laura Andrau, Kelly Helen Anderson
-
Patent number: 9540379Abstract: The invention relates to (1,2,4)triazolo[4,3-a]quinoxaline derivatives which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases.Type: GrantFiled: January 30, 2012Date of Patent: January 10, 2017Assignee: Boehringer Ingelheim International GmbHInventors: Hans-Joachim Lankau, Barbara Langen, Christian Grunwald, Norbert Hoefgen, Hans Stange, Rita Dost, Ure Egerland
-
Patent number: 9511067Abstract: The invention relates to pyrrolopyrazine-spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.Type: GrantFiled: December 22, 2014Date of Patent: December 6, 2016Assignee: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Sara Sabina Hadida Ruah, Edward Adam Kallel, Mark Thomas Miller, Vijayalaksmi Arumugam, Jason McCartney, Corey Anderson, Peter Diederik Jan Grootenhuis, Licong Jiang
-
Patent number: 9499535Abstract: The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases.Type: GrantFiled: April 23, 2012Date of Patent: November 22, 2016Assignee: ORIGENIS GMBHInventors: Michael Thormann, Andreas Treml, Michael Almstetter, Roland Koestler, Nasser Yehia
-
Patent number: 9487539Abstract: Novel compound having the following formula: wherein Y is N, O, or S. Also disclosed are a pharmaceutical compositions comprising the same, methods for treating cancer using the same, and methods for the synthesis of the same. The novel compounds of the present invention are found to inhibit protein kinases, especially Checkpoint kinase Chk1/Chk2.Type: GrantFiled: July 17, 2014Date of Patent: November 8, 2016Inventor: Zhanggui Wu
-
Patent number: 9464093Abstract: This document relates to compounds and compositions useful for treating cancers, such as brain and nervous system cancers.Type: GrantFiled: October 11, 2013Date of Patent: October 11, 2016Assignees: Mayo Foundation for Medical Education and Research, Osaka UniversityInventors: Han W. Tun, Takehiko Yoshimitsu, Daisuke Shigeoka, Takuma Kamon, Zhimin Li, Yushi Qiu, Thomas R. Caulfield
-
Patent number: 9458159Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein L, R1, R5, W, X, Y1, Y2, and Z are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: GrantFiled: July 11, 2014Date of Patent: October 4, 2016Assignee: Gilead Sciences, Inc.Inventors: Manoj C. Desai, Mingzhe Ji, Haolun Jin, Teresa Alejandra Trejo Martin, Hyung-Jung Pyun
-
Patent number: 9446043Abstract: A pharmaceutical combination comprising (a) a protein kinase C (PKC) inhibitor compound, or a pharmaceutically acceptable salt thereof, and (b) at least one mitogen activated protein kinase (MEK) inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.Type: GrantFiled: November 26, 2013Date of Patent: September 20, 2016Assignee: Novartis AGInventors: Dale Porter, Caroline Emery, Lujian Tan, Padmaja Yerramilli-Rao